GCVI Summit 2018
Skip Content

6 October 2017

Rhythm Pharmaceuticals rides to $120m IPO

The Pfizer and Ipsen-backed metabolic disorder drug developer floated above its range and saw its share price rise more than 75% on its first day of trading.

Author: Robert Lavine, News Editor

Rhythm Pharmaceuticals, a US-based developer of treatments for metabolic disorders, raised $120m yesterday from an initial public offering that provided exits for pharmaceutical companies Pfizer and Ipsen.